For the yes
DOI:
https://doi.org/10.47196/diab.v56i3Sup.531Keywords:
diabetes mellitus, insulinAbstract
Since the publication of the DCCT in 1993, the type 1 diabetes standard treatment is based in an intensified plan of insulin administration with the aplication of several dosis of combined basal long action insulin and faster or ultrafast insulins before main meals.
This model of intensified insulin therapy ,however, does not always achieve goals of good glycemic control and is subject to great limitations since it concomitantly predisposes the patients with this disease to a higher risk of hypoglycemia and especially weight gain and development of metabolic syndrome The coexistence of type 1 diabetes and obesity with features of the classic insulinresistance syndrome (dual diabetes) ,of the type clasically seen in type 2 diabetes,can lead the type 1 diabetic patient with several years of evolution to a heightened risk of cardiometabolic and renal complications.The EDIC study showed that the greater the weight gain in type 1 diabetics,the greater the risk of cardiovascular events.
References
I. Vilarrasa N, San Jose P, Rubio MA, Lecube A. Obesity in diabetes in type I diabetes: links, risks and management challenges. Diabetes Metab Synd Obes 2021;14:2807-2827.
II. Petrie J, Chaturvedi N, Ford I, Browers M, et al.; for the Removal study group. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL). A double blind, randomized, placebo controlled trial. Lancet Diabetes & Endocrinol 2017;5:597-609
III. Buse JB, Garg SK, Rosentok J, Bailey TS, et al. Sotaglifozin in combination with optimized insulin therapy in adults with type 1 diabetes:the norteamerican in tandem study. Diabetes Care 2018;41:9:1970-1980.
IV. Holth R, De Vries H, Hess Fischl, Hirsch I, et al. The management of type 1 diabetes in adults: a consensus report by the American Diabetes Association and the European Association for the Study of Diabetes (EASD). Diabetes Care2021;44:2589-2625.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 on behalf of the authors. Reproduction rights: Argentine Diabetes Society
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
